Monte Rosa Therapeutics (GLUE) News Today $4.16 -0.08 (-1.77%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) Head-To-Head ContrastMay 30 at 1:45 AM | americanbankingnews.comMonte Rosa Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28 at 7:00 AM | globenewswire.comVestal Point Capital LP Sells 505,000 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Vestal Point Capital LP lessened its position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 54.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 425,000 shares ofMay 21, 2025 | marketbeat.comSuvretta Capital Management LLC Sells 1,095,202 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Suvretta Capital Management LLC cut its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 41.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,563,798 shares of the company's stock afteMay 19, 2025 | marketbeat.comCubist Systematic Strategies LLC Makes New $644,000 Investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Cubist Systematic Strategies LLC acquired a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 92,818 shares of the company's stock, valued at approximately $644,000.May 18, 2025 | marketbeat.comParkwood LLC Sells 103,620 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Parkwood LLC cut its position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 24.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 323,000 shares of the company's stock after selling 103,620 shares during the period. ParkwMay 16, 2025 | marketbeat.comAnalysts Set Expectations for GLUE Q4 EarningsMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Stock analysts at Wedbush issued their Q4 2026 earnings estimates for Monte Rosa Therapeutics in a research report issued on Thursday, May 8th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.57) per sharMay 14, 2025 | marketbeat.comMonte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business UpdatesMay 8, 2025 | globenewswire.comBVF Inc. IL Invests $19.19 Million in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)BVF Inc. IL acquired a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,764,471 shares of the company's stock, valuMay 6, 2025 | marketbeat.comMonte Rosa Therapeutics (GLUE) Expected to Announce Earnings on ThursdayMonte Rosa Therapeutics (NASDAQ:GLUE) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-monte-rosa-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Increases Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Price T Rowe Associates Inc. MD grew its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 7.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,116,637 shares of the company'sMay 2, 2025 | marketbeat.comMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast CancerApril 28, 2025 | globenewswire.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Marshall Wace LLPMarshall Wace LLP raised its position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 187.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 499,492 shares of the company's stock after puApril 28, 2025 | marketbeat.comAvoro Capital Advisors LLC Has $30.15 Million Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Avoro Capital Advisors LLC cut its position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 25.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,345,000 shares of the company's stock aApril 23, 2025 | marketbeat.comJump Financial LLC Buys Shares of 154,842 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Jump Financial LLC purchased a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 154,842 shares of the company's stock, valued atApril 23, 2025 | marketbeat.comMonte Rosa Therapeutics Insider Ups Holding During YearApril 22, 2025 | finance.yahoo.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Down 23.0% in MarchMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totalling 5,410,000 shares, a decline of 23.0% from the March 15th total of 7,030,000 shares. Based on an average trading volume of 785,800 shares, the days-to-cover ratio is currently 6.9 days. Currently, 11.8% of the company's stock are short sold.April 21, 2025 | marketbeat.comVanguard Group Inc. Buys 622,134 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Vanguard Group Inc. increased its stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 24.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,156,354 shares of the company's stock after purchasingApril 17, 2025 | marketbeat.comNorges Bank Takes Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Norges Bank acquired a new position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 445,868 shares of the company's stock, valued at approximatelyApril 13, 2025 | marketbeat.comShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Drops By 12.6%Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 7,030,000 shares, a decline of 12.6% from the February 28th total of 8,040,000 shares. Based on an average daily trading volume, of 805,300 shares, the short-interest ratio is currently 8.7 days. Approximately 15.3% of the company's stock are sold short.April 3, 2025 | marketbeat.comVersant Venture Management LLC Purchases New Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Versant Venture Management LLC acquired a new position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 5,652,922 shares of the company's stock, valued at aMarch 27, 2025 | marketbeat.comInsider Buying: Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Buys 10,000 Shares of StockMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) Director Chandra P. Leo acquired 10,000 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were acquired at an average cost of $5.84 per share, with a total value of $58,400.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $58,400. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 26, 2025 | marketbeat.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Acquires $58,400.00 in StockMarch 26, 2025 | insidertrades.comMonte Rosa Therapeutics: Exercise Extreme CautionMarch 25, 2025 | seekingalpha.comFY2029 Earnings Estimate for GLUE Issued By WedbushMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Equities researchers at Wedbush issued their FY2029 earnings per share estimates for shares of Monte Rosa Therapeutics in a research note issued to investors on Thursday, March 20th. Wedbush analyst R. Driscoll forecasts that the companyMarch 24, 2025 | marketbeat.comMonte Rosa Therapeutics price target raised to $17 from $15 at WedbushMarch 23, 2025 | markets.businessinsider.comMonte Rosa Therapeutics price target lowered to $10 from $11 at Wells FargoMarch 22, 2025 | markets.businessinsider.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comMonte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $10.00 at Wells Fargo & CompanyWells Fargo & Company decreased their price target on Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating for the company in a report on Friday.March 22, 2025 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)March 22, 2025 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)March 22, 2025 | markets.businessinsider.comMonte Rosa Therapeutics Earnings Call Highlights Progress and Strategic ShiftsMarch 21, 2025 | tipranks.comMonte Rosa Therapeutics (NASDAQ:GLUE) Earns Outperform Rating from WedbushWedbush reaffirmed an "outperform" rating and set a $17.00 target price (up from $15.00) on shares of Monte Rosa Therapeutics in a research report on Thursday.March 21, 2025 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Posts Earnings Results, Beats Expectations By $0.50 EPSMonte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) announced its earnings results on Thursday. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.50.March 21, 2025 | marketbeat.comMonte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9MMarch 21, 2025 | markets.businessinsider.comMonte Rosa Therapeutics files $400M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comMonte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call TranscriptMarch 21, 2025 | seekingalpha.comMixed data results for two Monte Rosa molecular glue degradersMarch 21, 2025 | finance.yahoo.comMonte Rosa Therapeutics shares surge on strong Q4 revenue beatMarch 20, 2025 | in.investing.comMonte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 ProgramsMarch 20, 2025 | globenewswire.comBrokers Offer Predictions for GLUE FY2024 EarningsMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Analysts at Lifesci Capital issued their FY2024 EPS estimates for Monte Rosa Therapeutics in a note issued to investors on Wednesday, March 12th. Lifesci Capital analyst O. Mccammon anticipates that the company will post earnings per shaMarch 15, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform RecommendationMarch 13, 2025 | msn.comLifesci Capital Initiates Coverage on Monte Rosa Therapeutics (NASDAQ:GLUE)Lifesci Capital initiated coverage on Monte Rosa Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $19.00 price target for the company.March 13, 2025 | marketbeat.comMonte Rosa Therapeutics initiated with an Outperform at LifeSci CapitalMarch 12, 2025 | markets.businessinsider.comAlphaQuest LLC Takes $657,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)AlphaQuest LLC purchased a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 94,633 shares of the company's stock, valued at approximately $657,000. AlphaQuest LLC owned about 0.15% of MMarch 12, 2025 | marketbeat.comMonte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025March 11, 2025 | globenewswire.comMonte Rosa Therapeutics (GLUE) Projected to Post Earnings on ThursdayMonte Rosa Therapeutics (NASDAQ:GLUE) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comMonte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest UpdateMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 8,070,000 shares, a decline of 7.9% from the January 15th total of 8,760,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is currently 7.0 days. Approximately 17.6% of the company's stock are sold short.February 18, 2025 | marketbeat.comShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Grows By 8.8%Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 9,140,000 shares, an increase of 8.8% from the December 31st total of 8,400,000 shares. Currently, 19.9% of the company's stock are sold short. Based on an average trading volume of 2,760,000 shares, the short-interest ratio is presently 3.3 days.February 2, 2025 | marketbeat.com Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address GLUE Media Mentions By Week GLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLUE News Sentiment▼0.940.88▲Average Medical News Sentiment GLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLUE Articles This Week▼32▲GLUE Articles Average Week Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLYS News RCUS News PAHC News ARDX News WVE News COLL News SYRE News SNDX News GYRE News AVDL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLUE) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLUE Stock Free GLUE Stock Alerts